A much-anticipated FDA reform bill is signed into law: Progress and compromise Steven E. Nissen Invited Commentary 04 May 2008 Pages: 79 - 80
Inflammation at the islets of Langerhans and its role for the pathogenesis of type 2 diabetes Anette-G. ZieglerMarkus WalterHeike Boerschmann Clinical Trials Report 04 May 2008 Pages: 85 - 86
Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization Peter AchenbachJennifer BarkerEzio Bonifacio OriginalPaper 04 May 2008 Pages: 87 - 93
Latent (slowly progressing) autoimmune diabetes in adults Jochen Seissler OriginalPaper 04 May 2008 Pages: 94 - 100
T cells in the pathogenesis of type 1 diabetes Roberto MallonePeter van Endert OriginalPaper 04 May 2008 Pages: 101 - 106
Immunomodulation of autoimmune diabetes by dendritic cells Klaus PechholdKerstin Koczwara OriginalPaper 04 May 2008 Pages: 107 - 113
Intensive diabetes treatment and cognition: No long-lasting effects of recurrent hypoglycemia Katie Weinger Clinical Trials Report 04 May 2008 Pages: 117 - 118
Psychosocial and behavioral aspects of diabetic foot lesions Loretta Vileikyte OriginalPaper 04 May 2008 Pages: 119 - 125
Behavioral aspects of weight loss in type 2 diabetes Rena R. WingBecky Marquez OriginalPaper 04 May 2008 Pages: 126 - 131
Genetics of metabolic syndrome Tisha JoyPiya LahiryRobert A. Hegele OriginalPaper 04 May 2008 Pages: 141 - 148
TCF7L2 genetic defect and type 2 diabetes Stéphane CauchiPhilippe Froguel OriginalPaper 04 May 2008 Pages: 149 - 155
Genes and nonalcoholic fatty liver disease Nimantha Mark Wilfred de AlwisChristopher Paul Day OriginalPaper 04 May 2008 Pages: 156 - 163
